A detailed history of Captrust Financial Advisors transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 13,386 shares of IBRX stock, worth $27,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,386
Previous 10,741 24.63%
Holding current value
$27,842
Previous $32,000 9.38%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$1.89 - $3.44 $4,999 - $9,098
2,645 Added 24.63%
13,386 $35,000
Q1 2025

May 14, 2025

BUY
$2.32 - $3.9 $24,919 - $41,889
10,741 New
10,741 $32,000
Q3 2024

Nov 14, 2024

BUY
$3.32 - $6.7 $36,762 - $74,189
11,073 New
11,073 $41,000
Q3 2021

Nov 16, 2021

BUY
$9.17 - $14.24 $17,606 - $27,340
1,920 New
1,920 $19,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $833M
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.